Kings Path Partners LLC decreased its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) by 38.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,850 shares of the technology company's stock after selling 8,710 shares during the quarter. Kings Path Partners LLC owned approximately 0.07% of Simulations Plus worth $340,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Proficio Capital Partners LLC bought a new stake in shares of Simulations Plus in the fourth quarter valued at about $719,000. D. E. Shaw & Co. Inc. raised its holdings in shares of Simulations Plus by 100.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 53,332 shares of the technology company's stock valued at $1,487,000 after purchasing an additional 26,661 shares in the last quarter. Sei Investments Co. bought a new stake in shares of Simulations Plus in the 4th quarter valued at about $330,000. Northern Trust Corp raised its holdings in shares of Simulations Plus by 10.0% in the 4th quarter. Northern Trust Corp now owns 236,373 shares of the technology company's stock valued at $6,592,000 after purchasing an additional 21,453 shares in the last quarter. Finally, AlphaQuest LLC raised its holdings in shares of Simulations Plus by 502.9% in the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company's stock valued at $75,000 after purchasing an additional 2,243 shares in the last quarter. Institutional investors own 78.08% of the company's stock.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. KeyCorp upped their target price on Simulations Plus from $32.00 to $40.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Wall Street Zen raised Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Simulations Plus currently has a consensus rating of "Moderate Buy" and an average price target of $50.00.
Check Out Our Latest Analysis on SLP
Insider Buying and Selling
In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $33.51, for a total transaction of $670,200.00. Following the sale, the director now owns 3,344,157 shares in the company, valued at approximately $112,062,701.07. The trade was a 0.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.40% of the stock is owned by company insiders.
Simulations Plus Trading Down 0.6%
Shares of SLP stock traded down $0.20 during trading hours on Friday, reaching $31.97. 137,865 shares of the company's stock were exchanged, compared to its average volume of 219,253. The stock's 50 day moving average is $30.38 and its 200-day moving average is $30.42. The company has a market cap of $642.95 million, a price-to-earnings ratio of 79.93 and a beta of 1.10. Simulations Plus, Inc. has a fifty-two week low of $23.01 and a fifty-two week high of $50.11.
Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million for the quarter, compared to analyst estimates of $21.93 million. During the same period in the prior year, the company posted $0.20 EPS. The firm's quarterly revenue was up 22.5% compared to the same quarter last year. Equities analysts anticipate that Simulations Plus, Inc. will post 1.09 EPS for the current year.
About Simulations Plus
(
Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
